Boronic acid, B-[(1R)-1-[[(2S)-2-[(2,6-difluorobenzoyl)amino]-1-oxo-3-phenylpropyl]amino]-3-methylbutyl]-

NIC-0102 is an orally bioavailable proteasome inhibitor. NIC-0102 specifically prevents NLRP3 inflammasome activation but has no effect on NLRC4 or AIM2 inflammasomes. In vitro studies revealed that NIC-0102 induced the polyubiquitination of NLRP3, interfered with the NLRP3?ASC interaction, and blocked ASC oligomerization, thereby resulting in the inhibition of NLRP3 inflammasome activation. In addition, NIC-0102 also inhibited the production of pro-IL-1β. Importantly, NIC-0102 showed potent anti-inflammatory effects on DSS-induced ulcerative colitis model in vivo.